Immune Gene Profiles Linked to Higher EBV DNA Levels in Nasopharyngeal Cancer

Nasopharyngeal carcinoma, a malignancy of the nasopharynx that arises in an anatomical crossroads between the nasal cavity and the throat, has long been recognized as one of the most striking examples of a human cancer driven by the interplay between viral infection and inherited immune variation. Virtually every nasopharyngeal carcinoma cell harbors the Epstein-Barr virus, a herpesvirus that infects the vast majority of the world’s population without consequence, yet only a small fraction of infected individuals ever develop the tumor. This paradox has pushed researchers to look beyond the virus itself and toward the genetic architecture of the host immune system, where molecules that govern how natural killer cells and cytotoxic T lymphocytes recognize infected or transformed cells may tip the balance between silent viral carriage and malignant transformation.

A new exploratory case-control study conducted at Wuzhou Red Cross Hospital in Guangxi, southern China, adds a detailed immunogenetic dimension to this question. The research, published in BMC Cancer, examined whether variation in killer-cell immunoglobulin-like receptors, or KIRs, and their HLA class I ligands is associated not only with susceptibility to nasopharyngeal carcinoma but also with the levels of circulating Epstein-Barr virus DNA measured in patients’ plasma before any treatment began. Pretreatment plasma viral DNA load is one of the most clinically consequential biomarkers in this disease, correlating with tumor burden, staging accuracy, treatment response, and prognosis, so understanding why some patients present with dramatically higher viral loads than others is a matter of genuine clinical interest.

The study enrolled 204 patients with histopathologically confirmed nasopharyngeal carcinoma and 201 healthy controls, all drawn from a region of southern China where the disease is markedly more common than in most of the world. The researchers genotyped the content of KIR genes, categorized individuals by gene-content-defined KIR haplotype combinations, distinguished between the two major structural subtypes of the activating receptor KIR2DS4, and typed HLA-A alleles. KIRs are a family of receptors expressed on natural killer cells and subsets of T cells; some KIRs carry inhibitory cytoplasmic motifs and dampen immune activation upon recognizing self-HLA, while others, such as KIR2DS4, deliver activating signals that can promote cytotoxicity against virus-infected or malignant cells. Because individual KIRs recognize specific HLA class I allotypes, the functional significance of any given KIR gene depends on which HLA alleles a person carries, making combined KIR/HLA profiles the most biologically meaningful unit of analysis.

Several differences emerged between patients and controls. Nasopharyngeal carcinoma patients showed higher detection frequencies of the genes encoding KIR2DS4 and the inhibitory receptor KIR3DL1, and a lower frequency of the BB category of gene-content-defined KIR haplotype combinations, a configuration typically associated with a richer repertoire of activating receptors. Among individuals positive for KIR2DS4, the Deleted/Deleted subtype, in which both copies of the gene carry a deletion that removes the D1 extracellular domain, was nominally enriched in patients. On the HLA side, the allele HLA-A11:01, which is common in East Asian populations, was less frequent among patients, whereas HLA-A02:07 was more frequent. These susceptibility associations were nominal rather than robust to multiple-testing correction, and the authors are careful to frame them as exploratory observations that require independent validation.

The most striking finding of the study came from the case-only phenotype analysis. Among 182 patients for whom pretreatment plasma Epstein-Barr virus DNA records were available, the researchers asked whether any KIR/HLA-A profile was associated with the magnitude of the viral load, analyzed as a log10-transformed continuous variable. Patients carrying the combined profile of HLA-A*11:01 negativity together with the KIR2DS4 Deleted/Deleted subtype had significantly higher pretreatment viral DNA levels than patients without this profile, with median log10 values of 3.94 versus 2.81, corresponding to roughly a thirteen-fold difference in raw viral copy numbers. The association remained significant after statistical adjustment for age, sex, clinical stage, and TNM-related variables, yielding a regression coefficient of 1.36 and a P value of 0.013, which indicates that the immunogenetic signal was not simply a proxy for more advanced disease at presentation.

The biological plausibility of this association rests on the mechanics of natural killer cell licensing and recognition. HLA-A11:01 is a ligand for several KIR receptors, and its presence can shape the education and reactivity of the natural killer cell repertoire. KIR2DS4 full-length, the intact form of the receptor, can recognize specific HLA-A allotypes and deliver activating signals, whereas the Deleted variant encodes a truncated receptor with altered ligand specificity. An individual who lacks HLA-A11:01 and carries only the Deleted form of KIR2DS4 may therefore present a configuration in which the activating arm of innate immunity is tuned differently, potentially allowing higher Epstein-Barr virus replication in the nasopharyngeal epithelium before immune control is established. Higher baseline viral replication would, in turn, be expected to produce the elevated plasma viral DNA loads observed in this subgroup, although the study design cannot establish this causal chain directly.

To probe the cellular correlates of these genetic associations, the researchers performed exploratory flow-cytometric analyses in tissue-source-specific subsets. At the sample level, they observed a positive correlation between peripheral-blood lymphocyte-related signals for KIR2DS4 positivity and NKG2D positivity, NKG2D being an activating receptor that recognizes stress-induced ligands on infected and transformed cells. This correlation suggests that the two activating receptor systems may mark overlapping or co-stimulated lymphocyte populations in the circulation. In tumor-infiltrating cytotoxic T lymphocytes, NKG2D positivity showed a nominal difference according to Epstein-Barr virus DNA level, but this observation did not withstand correction for multiple comparisons, underscoring the preliminary nature of the cellular findings.

The study also examined whether longitudinal Epstein-Barr virus DNA kinetic variables, such as the rate of viral load decline during treatment, were associated with KIR/HLA-A profiles, and found no stable relationships. This negative result is informative in itself: it suggests that the immunogenetic variation captured by KIR2DS4 and HLA-A typing relates to the baseline viral burden at diagnosis rather than to the dynamics of viral clearance once therapy begins. In other words, inherited immune receptor configurations may influence how much virus circulates before treatment, while treatment response and viral kinetics are governed by other determinants, including tumor biology and the intensity of cytoreductive therapy.

The authors emphasize several caveats that temper the strength of their conclusions. The study was single-center, the sample sizes, while adequate for detecting moderate effects, are modest by the standards of immunogenetic association studies, and the large number of KIR and HLA comparisons performed means that some nominally significant findings, including the susceptibility associations with KIR2DS4, KIR3DL1, HLA-A11:01, and HLA-A02:07, could reflect chance. The pretreatment viral DNA association, which survived multivariable adjustment, is the most robust signal in the dataset, but even it is explicitly labeled hypothesis-generating and requires replication in independent cohorts, ideally from different geographic regions where both the allele frequencies and the intensity of Epstein-Barr virus exposure may differ.

Nevertheless, the work opens a concrete line of investigation into why pretreatment plasma viral DNA, one of the most powerful prognostic markers in nasopharyngeal carcinoma, varies so widely between patients at the same clinical stage. If the HLA-A*11:01-negative/KIR2DS4 Deleted/Deleted profile is confirmed in larger and more diverse cohorts, it could eventually help stratify patients at diagnosis, refine the interpretation of viral DNA measurements, and illuminate the innate immune mechanisms that normally keep Epstein-Barr virus in check in the nasopharynx. The study was supported by the Natural Science Foundation of Guangxi, the National Natural Science Foundation of China, and the Health Commission of Wuzhou City, and was conducted with ethics approval and written informed consent from all participants, with all data anonymized before analysis.

Subject of Research: Immunogenetic associations between KIR2DS4/HLA-A profiles and Epstein-Barr virus DNA levels in nasopharyngeal carcinoma

Article Title: Exploratory associations of KIR2DS4/HLA-A immunogenetic profiles with nasopharyngeal carcinoma susceptibility and pretreatment plasma EBV DNA phenotypes

Article References: Ye, J., Jiang, X., Ma, H., Huang, H., Gao, T., Zhang, B., Luo, Y., & Tang, M. (2026). Exploratory associations of KIR2DS4/HLA-A immunogenetic profiles with nasopharyngeal carcinoma susceptibility and pretreatment plasma EBV DNA phenotypes. BMC Cancer. https://doi.org/10.1186/s12885-026-17013-y

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17013-y

Keywords: nasopharyngeal carcinoma, Epstein-Barr virus, KIR2DS4, HLA-A, immunogenetics, natural killer cells, EBV DNA, case-control study, KIR receptors, viral load, cancer susceptibility, BMC Cancer